Selumetinib-A Comprehensive Review of the New FDA-Approved Drug for Neurofibromatosis.
作者信息
Gorai Surajit, Rathore Gyanesh, Das Kinnor
机构信息
Department of Dermatology, Day Care Building, Apollo Multispeciality Hospital, Kolkata, West Bengal, India.
出版信息
Indian Dermatol Online J. 2024 Jun 26;15(4):701-705. doi: 10.4103/idoj.idoj_569_23. eCollection 2024 Jul-Aug.
Abstract
摘要
相似文献
1
Selumetinib-A Comprehensive Review of the New FDA-Approved Drug for Neurofibromatosis.
Indian Dermatol Online J. 2024 Jun 26;15(4):701-705. doi: 10.4103/idoj.idoj_569_23. eCollection 2024 Jul-Aug.
2
A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Ann Pharmacother. 2022 Jun;56(6):716-726. doi: 10.1177/10600280211046298. Epub 2021 Sep 18.
3
Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT.
Future Oncol. 2024 May;20(14):877-890. doi: 10.2217/fon-2023-0565. Epub 2024 Feb 22.
4
Precision oncology in neurofibromatosis type 1: quantification of differential sensitivity to selumetinib in plexiform neurofibromas using single-cell RNA sequencing.
J Neurooncol. 2024 Aug;169(1):147-153. doi: 10.1007/s11060-024-04711-5. Epub 2024 May 13.
5
Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity.
Neuro Oncol. 2022 Nov 2;24(11):1978-1988. doi: 10.1093/neuonc/noac109.
6
Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
Cancer Chemother Pharmacol. 2021 Aug;88(2):189-202. doi: 10.1007/s00280-021-04274-6. Epub 2021 Apr 26.
7
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943.
8
FDA Approval Summary: Selumetinib for Plexiform Neurofibroma.
Clin Cancer Res. 2021 Aug 1;27(15):4142-4146. doi: 10.1158/1078-0432.CCR-20-5032. Epub 2021 Mar 12.
9
Selumetinib: First Approval.
Drugs. 2020 Jun;80(9):931-937. doi: 10.1007/s40265-020-01331-x.
10
Effect of food on selumetinib pharmacokinetics and gastrointestinal tolerability in adolescents with neurofibromatosis type 1-related plexiform neurofibromas.
Neurooncol Adv. 2024 Mar 16;6(1):vdae036. doi: 10.1093/noajnl/vdae036. eCollection 2024 Jan-Dec.
本文引用的文献
1
Neurofibromatosis Type 1 with a Giant Diffuse Plexiform Neurofibroma Invading the Liver.
Intern Med. 2023 Oct 15;62(20):2971-2975. doi: 10.2169/internalmedicine.1372-22. Epub 2023 Feb 15.
2
Selumetinib for Refractory Pulmonary and Gastrointestinal Bleeding in Noonan Syndrome.
Pediatrics. 2022 Oct 1;150(4). doi: 10.1542/peds.2022-056336.
3
Effect of food on capsule and granule formulations of selumetinib.
Clin Transl Sci. 2022 Apr;15(4):878-888. doi: 10.1111/cts.13209. Epub 2022 Feb 15.
4
Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.
Adv Cancer Res. 2022;153:101-130. doi: 10.1016/bs.acr.2021.07.008. Epub 2021 Sep 2.
5
Efficacy and Safety of Selumetinib in Pediatric Patients With Neurofibromatosis Type 1: A Systematic Review and Meta-analysis.
Neurology. 2022 Mar 1;98(9):e938-e946. doi: 10.1212/WNL.0000000000013296. Epub 2022 Jan 11.
6
Treatment of Plexiform Neurofibromas with MEK Inhibitors: First Results with a New Therapeutic Option.
Neuropediatrics. 2022 Feb;53(1):52-60. doi: 10.1055/s-0041-1740549. Epub 2021 Dec 14.
7
A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Ann Pharmacother. 2022 Jun;56(6):716-726. doi: 10.1177/10600280211046298. Epub 2021 Sep 18.
8
Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
Cancer Chemother Pharmacol. 2021 Aug;88(2):189-202. doi: 10.1007/s00280-021-04274-6. Epub 2021 Apr 26.
9
Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.
Curr Oncol Rep. 2021 Mar 15;23(4):45. doi: 10.1007/s11912-021-01032-y.
10
FDA Approval Summary: Selumetinib for Plexiform Neurofibroma.
Clin Cancer Res. 2021 Aug 1;27(15):4142-4146. doi: 10.1158/1078-0432.CCR-20-5032. Epub 2021 Mar 12.
Zotero 插件